consumers are asking for generic medications that look more distinctive—certainly, looking like the brand product would help achieve this goal. While we support the right of pharmaceutical ...

Also, social media has somewhat hyped the benefits of these medications ... AstraZeneca also bought rights to AZD5004, a small-molecule oral GLP-1 receptor, from a Chinese biotech in November ...

today announced that it has acquired the U.S. rights to Amglidia (glyburide oral suspension, known as glibenclamide in Europe) for the treatment of neonatal diabetes mellitus from AMMTeK.

To foray into the lucrative obesity market, Merck MRK announced that it is in-licensing global rights to an investigational oral GLP-1 receptor ... the benefits of these medications.